ALGS
Aligos Therapeutics, Inc. Common Stock
stockNASDAQ
aligos therapeutics, inc., a biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. its lead drug candidate is alg-010133, a synthetic oligonucleotide that is in phase i clinical trial for the treatment of chronic hepatitis b (chb). the company is also developing alg-000184, a capsid assembly modulator to treat chb; alg-020572, a oligonucleotide for the treatment of chb; alg-125097, an sirna drug candidate to treat chb; and alg-055009, a small molecule thr-ã agonist for the treatment of non-alcoholic steatohepatitis. aligos therapeutics, inc. was founded in 2018 and is headquartered in south san francisco, california.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.07 | 2026-11-06 | -48.16% | 6.262 |
| 1M | 5.51 | 2026-10-13 | -61.71% | 1.660 |
| 3M | 6.77 | 2026-08-13 | -68.83% | 1.815 |
| 6M | 6.67 | 2026-05-13 | -68.37% | 1.682 |
| 1Y | 6.07 | 2025-11-13 | -65.24% | 1.442 |
| 2Y | 19.58 | 2024-11-13 | -89.22% | — |
| 5Y | 430.25 | 2021-11-12 | -99.51% | 1.461 |
Aligos Therapeutics, Inc. Common Stock (NASDAQ:ALGS) stock price today is $2.11, and today's volume is 57,515. ALGS is up 6.566% today. The 30 day average volume is 54,790. ALGS market cap is $13.18M with 6.25M shares outstanding.